Anirban Maitra, Professor of Pathology and Medicine at NYU Langone Health, shared a post on LinkedIn:
“Really enjoyed contributing to this Cancer Cell by Cell Press paper led by Van Morris with Scott Kopetz and many others from MD Anderson Cancer Center.
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
The BRAF V600E subset of Colorectal Cancer is a challenging disease, and Scott and colleagues have been plugging away at it with the BREAKWATER trial. This triple regimen adds more firepower including some long term durable responses.
Our contribution centered on transcriptomic assessment of circulating extra cellular vesicle RNA (evRNA), which provided surprisingly robust discrimination for responders versus rapid progressors.
Kudos to Vahid Bahrambeigi, MS, PhD, MB (ASCP) Paola A. Guerrero, PhD Kimal Rajapakshe for this work.
This was a great example of team science!
Hope you enjoy the paper.”
Title: Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
Authors: Van K. Morris, Christine M. Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal, Kangyu Lin, Kanwal P.S. Raghav, Robert A. Wolff, Arvind Dasari, Ryan W. Huey, Bryan K. Kee, Michael J. Overman, Jason A. Willis, Phat H. Le, Michelle Escano, Yunyu C. Baig, Kelsey Pan, David Menter, Alda L. Tam, Wai C. Foo, Li Shen, Hey Min Lee, Thomas D. Gallup, Cori Margain, Dave Gallup, Kimal I. Rajapakshe, Paola A. Guerrero, Jing Wang, Ryan B. Corcoran, Anirban Maitra, Kyuson Yun, Scott Kopetz
Read the Full Article on Cancer Cell by Cell Press
More posts featuring Anirban Maitra.